On November 14, 2023, Eterna Therapeutics Inc. (Company) entered into an Exclusive Amended and Restated License Agreement (A&R Agreement) with Factor Bioscience Limited (Factor) to replace in its entirety the Exclusive License Agreement dated February 20, 2023, as amended on July 12, 2023. The A&R Agreement provides for, among other things, the expansion of the Company?s license rights to include (i) know-how that is necessary or reasonably useful to practice to the licensed patents and (ii) the ability to sublicense through multiple tiers (as opposed to only permitting a direct sublicense). The A&R Agreement also provides for technology transfer to Eterna, subject to the use restrictions in the A&R Agreement and reduces the termination rights of Factor under the A&R Agreement.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.83 USD | 0.00% | +3.98% | +1.95% |
May. 14 | Eterna Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
May. 08 | Eterna Therapeutics Inc. Appoints Mahendra Rao to Its Scientific Advisory Board | CI |
1st Jan change | Capi. | |
---|---|---|
+1.95% | 9.9M | |
+19.92% | 44.48B | |
+44.19% | 40.57B | |
-8.59% | 38.82B | |
+33.77% | 32.22B | |
-8.34% | 27.84B | |
+15.48% | 26.79B | |
+49.15% | 14.31B | |
+36.04% | 12.7B | |
-6.91% | 11.23B |
- Stock Market
- Equities
- ERNA Stock
- News Eterna Therapeutics Inc.
- Eterna Therapeutics Inc. Enter into an Exclusive Amended and Restated License Agreement with Factor Bioscience Limited